EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Liudmila Iamukova iD, Elena Alferova

Asia-Pacific Journal of Clinical Oncology · 2026-06 · 22 (3) · 362-368

DOI: 10.1111/ajco.70006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 22.08.2025. Verfasst von Liudmila Iamukova und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities.

Methods

A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database as of November 25, 2024. We conducted an analysis of the studies based on sponsors, conditions, phases, types of vaccines, and global geographic distribution.

Results

The majority of trials focused on peptide vaccines (40%) and dendritic cell vaccine (19%), targeting solid tumors, brain, pancreatic and breast cancers, among others. Phase 1 trials dominated the landscape, accounting for over 90% of studies, with significant activity in the United States (44%) and China (24%). Industry sponsors backed 22% of studies. Active trials represented 72% of the dataset, reflecting ongoing research efforts in this field. Enrollment sizes varied widely, ranging from small exploratory cohorts of fewer than 10 participants to larger‐scale trials enrolling up to 700 patients. Completed clinical trials evaluating personalized neoantigen vaccines across various cancer types showed that vaccines were generally well‐tolerated, elicited strong T‐cell responses, and resulted in promising clinical outcomes such as tumor shrinkage or prolonged progression‐free survival, particularly in melanoma, glioblastoma, and urothelial cancer, although no universal cure was demonstrated.

Conclusions

There is a broad early‐stage pipeline of personalized cancer vaccines currently being tested in clinical trials for various cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesPrecision MedicineNeoplasmsHumansClinical Trials as Topic

Stichwörter der Autor:innen

clinical trialsdendritic cell vaccineneoantigen cancer vaccinepeptide vaccinepersonalized cancer vaccine

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • School of Pharmacy, University of California San Diego, La Jolla, California, USA.
  • Clinical Trial Office, Moores Cancer Center, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Liudmila Iamukova

Zitieren

APA

Iamukova, L., & Alferova, E. (2026). Personalized Cancer Vaccines in the Clinical Trial Pipeline. Asia-Pacific Journal of Clinical Oncology, 22(3), 362-368. https://doi.org/10.1111/ajco.70006

Vancouver

Iamukova L, Alferova E. Personalized Cancer Vaccines in the Clinical Trial Pipeline. Asia-Pacific Journal of Clinical Oncology. 2026;22(3):362-368. doi:10.1111/ajco.70006

BibTeX
@article{Iamukova2026,
  author = {Iamukova, Liudmila and Alferova, Elena},
  title = {Personalized Cancer Vaccines in the Clinical Trial Pipeline},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {362--368},
  doi = {10.1111/ajco.70006}
}
Kostenlos starten →